Search

C28H31N8O8Co, monoclinic, P21/c (no. 14), a = 14.8071(17) Å, b = 19.676(2) Å, c = 10.8580(13) Å, V = 3066.7(6) Å3, Z = 4, Rgt(F) = 0.0377, wRref(F2) = 0.1228, T = 293(2) K.

Reaction of 2-(1-methyl-1,2-dihydroimidazol-3-yl)acetonitrile tetrafluoroborate with silver oxide in dichloromethane readily yields [Ag(DIM)2]BF4, where DIM is 2-(1-methyl-1, 2-dihydroimidazol-3-yl)acetonitrile, representing a carbene organic ligand. The title compound was characterized by elemental analysis, IR, MS and single crystal X-ray diffraction. The crystal is of monoclinic system, space group C2/c with a = 14.010(18), b = 8.303(11), c = 14.936(20) A, β = 93.910(4)°, V = 1639(4) A3, Z = 4, Dx = 1.771 g/cm3, F (000) = 864, µ(MoKα) = 1.278 mm–1. The final R1 = 0.0711 and wR2 = 0.1903 for reflections with I > 2σ(I). In addition, the preliminary biological test showed that the title compound had anti-fungus yeast activity.

The title compound, 3-(2,4-dichlorophenyl)-2-phenyl-5-(p-tolyl)- 7-(trifluoromethyl)pyrazolo[1,5-a] pyrimidine (C26H16Cl2F3N3, Mr = 498.32) has been synthesized by condensation of 4,4,4-trifluoro-1-(p-tolyl)butane- 1,3-dione with 4-(2,4-dichlorophenyl)-3-phenyl-1H-pyrazol-5-amine. The latter was prepared from 2,4-dichlorophenylaceton itrile and ethyl benzoate through Claisen condensation and then cyclization with hydrazine hydrate. The crystal structure of the title compound was determined. In addition, the title compound possesses marked inhibition against the proliferation of human lung adenocarcinoma cell line A549 and human gastric cancer cell line MKN45, displaying promising anticancer activities.

The complexes {[Zn(1,3-bip)(3,5-pdc)]·2H2O}n and {[Cu(1,3-bip)(1,3-bdc)]·H2O}n, [1,3-bip=1,3-bis(imidazole)propane, 3,5-pdc=pyridine-3,5-dicarboxylic acid, 1,3-bdc=isophthalic acid], have been synthesised under hydrothermal conditions and structurally characterised. Their thermogravimetric and photoluminescence properties were also investigated.

The crystal structure of 5-chloro-3-(2,4-dichlorophenyl)-N-(3-methoxyphenyl)-2-methyl-6-phenylpyrazolo[1,5-a]pyrimidin-7-amine (C26H19Cl3N4O, Mr = 509.80) has been synthesised by chlorination and aminisation from 3-(2,4-dichlorophenyl)-2-methyl-6-phenylpyrazolo[1,5-a]pyrimidine-5,7-diol. Its structure was confirmed by element analysis, IR, 1H NMR and X-ray diffraction. The crystal belongs to the triclinic system, space group P-1 with a = 10.979(2) Å, b= 11.339(2) Å, c= 11.646(2) Å, a= 98.58(3) °, β= 110.21(3) °, γ= 111.61 (3) °. In addition, the compound possesses moderate anticancer activity.

The title compound, diethyl-2-[5-(4-fluorophenyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamido]pentanedioate (C23H22F4N4O5, Mr = 510.45) was synthesised and structurally characterised by element analysis, IR, 1H NMR and single crystal X-ray diffraction. The crystal belongs to the monoclinic system, space group C121 with a=27001(3) Å, b=7.161(1) Å, c = 12.0900 Å, α=90.00 °, β=92.379 (7) °, λ=90.00 °. In the crystal structure, the dihedral angles between the benzene ring and pyrazolopyrimidine are 53.618(162)°. Through C-H…F and C-H…O weak hydrogen bonds among molecules, the whole molecule is stacked into a three-dimensional structure. In addition, the compound possesses a moderate antituberculosis activity.